BB Biotech’s argenx ARGX Stock Holding History

BB Biotech’s Portfolio ARGX Stock Details ARGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$113M	Buy	904,739 +20,000	+2%	+$2.35M	2.84%	13
2018 Q4	$85M	Buy	884,739 +150,000	+20%	+$13.3M	2.72%	13
2018 Q3	$55.7M	Buy	734,739 +285,690	+64%	+$25.3M	1.47%	21
2018 Q2	$37.2M	Buy	449,049 +52,230	+13%	+$4.67M	1.07%	23
2018 Q1	$31.9M	Buy	+396,819	New	+$30M	0.88%	24

Other funds holding ARGX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BB Biotech's ARGX Position: Q1 2019 in Review

BB Biotech increased its argenx (ARGX) stake by 2.3% in Q1 2019, buying an estimated $2.35M and bringing the position to 904,739 shares worth $113M. The position accounts for 2.84% of the portfolio, ranked #13.

BB Biotech first reported a position in ARGX in Q1 2018 and has held it in 5 quarters since. 133 funds tracked by Wall St. Rank hold ARGX as of Q1 2019.

BB Biotech held 904,739 shares of argenx worth $113M as of Q1 2019.
BB Biotech bought 20,000 argenx shares in Q1 2019, an estimated $2.35M.
argenx made up 2.84% of BB Biotech's portfolio in Q1 2019, its #13 holding.
BB Biotech first reported a position in argenx in Q1 2018 and has held it in 5 quarters since.
133 funds tracked by Wall St. Rank held argenx as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.